Xingmou Biotech Secures Tens of Millions of RMB in Pre-A+ Financing to Advance Ophthalmic Gene Therapy Pipeline

StarryGene is a high-tech enterprise that develops cutting-edge gene editing technologies and gene therapy products for ophthalmic diseases, focusing on the development of ophthalmic gene therapy drugs. The core team of StarryGene is a doctoral entrepreneurial team led by a "Distinguished Young Scholar," with two core technology platforms on the R&D side: the AAV-Antibody Gene Drug Platform (Dual-Antibody Optimization Platform, Capsid Screening Platform) and the Gene Editing Platform.

The company is committed to the development of domestically available ophthalmic gene therapy drugs in China, actively promoting the application of gene therapy in major ophthalmic indications. With ophthalmology as the breakthrough point, particularly focusing on common eye diseases such as age-related macular degeneration, the goal is to help people in China see longer and better.

Among them, "XMVA09 Injection," a Class I innovative gene therapy drug developed by StarryGene, isThe First Gene Therapy Drug with Dual-Specificity Targets and Intravitreal Injection Capsid, with indications for wet age-related macular degeneration (wAMD), has achieved significantly superior in vivo and in vitro efficacy compared to the leading U.S. product RGX-314. CurrentlyThe IND application for XMVA09 has been approved by the National Medical Products Administration (NMPA).The next phase will officially commence the Phase I/II clinical trials.